% | $
Quotes you view appear here for quick access.

Alkermes plc Message Board

  • stuey.olsen stuey.olsen Jul 13, 2013 4:51 PM Flag

    Parkinson's Disease Progress-ALKS

    Interesting updates on Parkinson's Disease progress. What is ALKS cut of Bydureon Rev?

    Google Exane

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I think it's 8%....
      (was a large holder of AMLN since 1996), now ALKS is my largest holding...

    • Encouraging when very limited choices are available for PD treatment.
      fResults. Exenatide was well tolerated, although weight loss was common and l-dopa dose failures occurred in a single patient. Single-blinded rating of the exenatide group suggested clinically relevant improvements in PD across motor and cognitive measures compared with the control group. Exenatide-treated patients had a mean improvement at 12 months on the MDS-UPDRS of 2.7 points, compared with mean decline of 2.2 points in control patients (P = 0.037).

      Conclusion. These results demonstrate a potential cost-efficient approach through which preliminary clinical data of possible biological effects are obtainable, prior to undertaking the major investment required for double-blind trials of a potential disease-modifying drug in PD.
      Trial registration. NCT01174810.

      See JCI for more details on this PD trial. 8% of PD & Dementia? Not sure of market potential.

    • AMLN had three drugs Symlin (sp), type 1 diabetes, Byetta, and Bydureon type 2, ALKS receives 8% royalties from sales of Bydureon. Good luck longs.

      Sentiment: Strong Buy

    • Perhaps chance correlation, very small study- but interesting news on dementia front.
      ......At both 12 and 14 months, a significant advantage in the Mattis dementia rating scale–2 (Mattis DRS-2) was seen in patients treated with exenatide, with a mean improvement of 2.8 points at 14 months compared with deterioration by a mean of 3.5 points in control patients....... See the JCI story if you google Exantide Alzheimer's.

    • Google "Exanetide Parkinson's", Yahoo would not let me post link. Bydureon is different form of Exanetide....I think the long acting? I wonder why this news to not post to Reuter's or other company news sites. Only the research sites.

55.80+0.06(+0.11%)May 6 4:00 PMEDT